Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Tom Dock from Noah's Animal Hospital joined "Life.Style.Live!" Host Marlee Thomas to discuss key tips for maintaining pet ...

We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other important ...

The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...

Merck & Co Inc (MRK) reports robust sales growth driven by KEYTRUDA and WINREVAIR, while navigating GARDASIL demand issues in ...

Investors have taken to punishing pharma companies that appear unable to gauge demand for their top products. Consider Pfizer. The company’s inability to accurately project demand for its Covid-19 ...

Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...

VBMA students are invited to compete in a scholarship program aiming to prepare the next generation of veterinarians for entrepreneurship ...

Q4 2024 Management View Rob Davis emphasized Merck's strong performance in 2024, driven by demand for KEYTRUDA, the launch of WINREVAIR, and robust growth in Animal Health. Davis highlighted ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Global pharmaceutical company Merck (NYSE:MRK) reported Q4 CY2024 results , with sales up 6.8% year on year to $15.62 billion ...